Company Filing History:
3 out of 1,722 
3 out of 687 
1 out of 135 
Years Active: 2020-2022
Title: Bo-Tsang Huang: Innovator in Cancer Therapy
Introduction
Bo-Tsang Huang is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of three patents, Huang is recognized for his work in developing novel therapeutic approaches.
Latest Patents
Huang's latest patents include the "PINK1 C-terminal domain polypeptide and methods using the same in cancer treatment." This patent describes a PINK1-C-terminal domain (PINK1-CTD) polypeptide that binds to the ERBB tyrosine kinase domain (ERBB-TKD), impeding ERBB from dimerization and activation. The PINK1-CTD polypeptide has shown potential in inhibiting, preventing, and treating ERBB-expressing cancers, providing a new direction for cancer therapy. Another notable patent is for "Antagonistic PDL1 aptamers and their applications in cancer therapy." This patent focuses on aptamers that bind to and antagonize PDL1, enhancing immune activity and offering treatment options for cancer and infectious diseases.
Career Highlights
Huang has had a distinguished career, working at esteemed institutions such as National Taiwan University and Academia Sinica. His research has been pivotal in advancing cancer treatment methodologies, and his patents reflect his commitment to improving patient outcomes.
Collaborations
Huang has collaborated with notable colleagues, including Pan-Chyr Yang and Pei-Ying Lin. These partnerships have contributed to the success of his research and the development of his patented inventions.
Conclusion
Bo-Tsang Huang is a key figure in the field of cancer therapy, with innovative patents that hold promise for future treatments. His work exemplifies the impact of research and innovation in addressing critical health challenges.